Biotech companies, especially small-cap ones, often have explosive growth potential. But that almost always comes with significant risks. Before investing in a small-cap biotech, it's essential to ensure there is more to it than exciting potential short-term gains. 

Let's look at one biotech company Wall Street thinks could skyrocket: bluebird bio (NASDAQ: BLUE). This gene-editing specialist has an average price target of $6.64, according to Yahoo! Finance, which implies an upside of 89% for the stock, as of this writing. Can Bluebird pull this off in the next year? Let's find out.

Bluebird currently has two products on the market. The first is Zynteglo, a treatment for transfusion-dependent beta-thalassemia (TDT), a rare blood disorder. The second is Skysona, a therapy that targets cerebral adrenoleukodystrophy (CALD), a rare pediatric neurological disorder. On the surface, it seems that Bluebird should be doing better than it has been.

Continue reading

Source Fool.com